A. Johnson

发表

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

G. Watts, K. Croft, D. Chan, 2003, Diabetes.

The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients

D. Nicol, R. Rigby, P. Taylor, 1999, Clinical pharmacology and therapeutics.

Short Report on DNA Marker at Candidate Locus

Anthony G. Johnson, D. Davis, A. Johnson, 1996 .

Human Epicardial Adipose Tissue Is a Source of Inflammatory Mediators

B. Goldstein, Anthony G. Johnson, A. Zalewski, 2003, Circulation.

New Strategies in Drug Discovery

J. D. Elliott, Eliot H Ohlstein, Anthony G Johnson, 2006, Methods in molecular biology.

Atorvastatin and Fenofibrate Have Comparable Effects on VLDL–Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome

G. Watts, D. Chan, P. Barrett, 2008, Arteriosclerosis, thrombosis, and vascular biology.

High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics.

P Hugh R Barrett, Dick C Chan, Gerald F Watts, 2006, The Journal of clinical endocrinology and metabolism.

Tumor Necrosis Factor-a and Interleukin-10 Genotypes in Congestive Heart Failure

N. Liyou, L. Simons, Anthony G. Johnson, 1999 .

Variations in the monoamine oxidase B lpar;MAOB) gene are associated with Parkinson's disease

D. Buchanan, D. L. Le Couteur, Anthony G. Johnson, 1999, Movement disorders : official journal of the Movement Disorder Society.

Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects

Anthony G. Johnson, Tuan Nguyen, D. Davis, 2001, Journal of hypertension.

Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.

G. Watts, K. Rye, Anthony G. Johnson, 2006, Clinical science.

A Prospective Evaluation of Discharge Efficiency in a University General Medical Unit

D. L. Couteur, A. Taylor, A. Johnson, 1997 .

Diverse Origin of Intimal Cells: Smooth Muscle Cells, Myofibroblasts, Fibroblasts, and Beyond?

A. Zalewski, Andrew Zalewski, Yi Shi, 2002, Circulation research.

Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo

G. Watts, K. Rye, Anthony G. Johnson, 2006, Clinical endocrinology.

Association of the SULT1A1 R213H polymorphism with colorectal cancer

Chung F. Wong, N. Liyou, B. Leggett, 2002, Clinical and experimental pharmacology & physiology.

No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation

B. Leggett, Joanne P Young, Anthony G. Johnson, 1999, Journal of gastroenterology and hepatology.

Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome

G. Watts, K. Rye, Anthony G. Johnson, 2009, Diabetes Care.

The Epidemiology of Parkinson’s Disease in an Australian Population

C. Brayne, A. Green, S. Pond, 1998, Neuroepidemiology.

The Serotonin Transporter Gene and Parkinson’s Disease

D. L. Le Couteur, S. Pond, G. Mellick, 2000, European Neurology.

Coronary artery disease is not associated with the E298 → D variant of the constitutive, endothelial nitric oxide synthase gene

Y. Friedlander, J. Simons, L. Simons, 1998, Clinical genetics.

The ACE Deletion Polymorphism Is Not Associated with Parkinson’s Disease

D. Buchanan, D. L. Le Couteur, D. Davis, 1999, European Neurology.

An Open Label, Randomised, Crossover, Comparative Study of Infusion Site Tolerability in Healthy Volunteers

M. Whitby, J. Stackelroth, D. Olesen, 1996 .

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

G. Watts, K. Croft, D. Chan, 2003, Diabetes.